SANES

10.692

+1.95%↑

BBVA

19.865

+2.56%↑

BNP

92.21

+2.54%↑

CABK

11.67

+1.97%↑

INGA

27.035

+2.21%↑

SANES

10.692

+1.95%↑

BBVA

19.865

+2.56%↑

BNP

92.21

+2.54%↑

CABK

11.67

+1.97%↑

INGA

27.035

+2.21%↑

SANES

10.692

+1.95%↑

BBVA

19.865

+2.56%↑

BNP

92.21

+2.54%↑

CABK

11.67

+1.97%↑

INGA

27.035

+2.21%↑

SANES

10.692

+1.95%↑

BBVA

19.865

+2.56%↑

BNP

92.21

+2.54%↑

CABK

11.67

+1.97%↑

INGA

27.035

+2.21%↑

SANES

10.692

+1.95%↑

BBVA

19.865

+2.56%↑

BNP

92.21

+2.54%↑

CABK

11.67

+1.97%↑

INGA

27.035

+2.21%↑

Kodu・Aktsiate loetelu・Bayer AG

Bayer AG

Avatud

SektorRahandus

38.65 0.55

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

38.39

Max

38.75

Põhinäitajad
By Trading Economics
Sissetulek	6.5B 2.8B
Müük	2B 13B
Aktsiakasum	2.812
Dividenditootlus	0.29
Kasumimarginaal	20.612
Töötajad	87,757
EBITDA	2.3B 4.4B

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+25.11% upside

Dividendid
By Dow Jones
Dividenditootlus Sektori keskmine	0.29% 4.64%
Järgmine tulemuste avaldamine	4. aug 2026

Turustatistika
By TradingEconomics
Turukapital	737M 37B
Eelmine avamishind	38.1
Eelmine sulgemishind	38.65

Uudiste sentiment

By Acuity

34%

66%

91 / 438 Pingereas Finance

Bayer AG Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

12. mai 2026, 11:24 UTC

Tulu

Suurimad hinnamuutused turgudel

Bayer Shares Climb After Earnings Beat Expectations

12. mai 2026, 06:10 UTC

Tulu

Bayer Net Profit Surges Driven by Growth in Agricultural Division

6. mai 2026, 10:51 UTC

Omandamised, ülevõtmised, äriostud

Bayer to Buy Eye-Drug Developer Perfuse Therapeutics for Up to $2.45 Billion -- Update

6. mai 2026, 07:01 UTC

Omandamised, ülevõtmised, äriostud

Bayer to Buy Eye-Drug Developer Perfuse Therapeutics for Up to $2.45 Billion

12. mai 2026, 12:05 UTC

Kuumad aktsiad

Stocks to Watch: GameStop, Venture Global, Wendy's, Hims & Hers -- WSJ

12. mai 2026, 10:51 UTC

Kuumad aktsiad

Stocks to Watch: GameStop, Venture Global, Hims & Hers, GoPro -- WSJ

12. mai 2026, 09:08 UTC

Kuumad aktsiad

Stocks to Watch: Venture Global, Hims & Hers, GoPro -- WSJ

12. mai 2026, 05:38 UTC

Tulu

Bayer Backs 2026 Outlook Adjusted for Currency

12. mai 2026, 05:36 UTC

Tulu

Bayer 1Q Consumer Health Sales Grew 5.3%, Adjusted for Currency, Portfolio Changes

12. mai 2026, 05:36 UTC

Tulu

Bayer 1Q Pharma Sales Fell 0.5%, Adjusted for Currency, Portfolio Changes

12. mai 2026, 05:36 UTC

Tulu

Bayer 1Q Crop Science Sales Grew 6.8%, Adjusted for Currency, Portfolio Changes

12. mai 2026, 05:35 UTC

Tulu

Bayer 1Q Adj EPS EUR2.71

12. mai 2026, 05:34 UTC

Tulu

Analysts Saw Bayer 1Q Net Profit From Continuing Operations at EUR1.60B

12. mai 2026, 05:34 UTC

Tulu

Analysts Saw Bayer 1Q Ebitda Before Special Items at EUR3.93B

12. mai 2026, 05:34 UTC

Tulu

Analysts Saw Bayer 1Q Sales at EUR13.42B

12. mai 2026, 05:34 UTC

Tulu

Bayer 1Q Sales Grew 4.1% When Adjusted for Currency, Portfolio Changes

12. mai 2026, 05:33 UTC

Tulu

Bayer 1Q EBIT EUR3.53B

12. mai 2026, 05:32 UTC

Tulu

Bayer 1Q Ebitda Before Special Items EUR4.45B

12. mai 2026, 05:32 UTC

Tulu

Bayer 1Q Net Pft EUR2.76B

12. mai 2026, 05:31 UTC

Tulu

Bayer 1Q Sales EUR13.405B

12. mai 2026, 05:31 UTC

Tulu

Bayer Backs 2026 View

6. mai 2026, 06:34 UTC

Omandamised, ülevõtmised, äriostud

Bayer: Perfuse's Lead Program Is Treatment for Glaucoma and Diabetic Retinopathy

6. mai 2026, 06:33 UTC

Omandamised, ülevõtmised, äriostud

Bayer: Acquisition Aims to Complement Ophthalmology Pipeline

6. mai 2026, 06:33 UTC

Omandamised, ülevõtmised, äriostud

Bayer: Additional Payments Subject to Development, Regulatory, and Commercial Milestones

6. mai 2026, 06:32 UTC

Omandamised, ülevõtmised, äriostud

Bayer to Pay $300M Upfront

6. mai 2026, 06:32 UTC

Omandamised, ülevõtmised, äriostud

Bayer to Buy Perfuse Therapeutics for Up to $2.45B

6. mai 2026, 06:31 UTC

Omandamised, ülevõtmised, äriostud

Bayer to Buy Perfuse Therapeutics

6. mai 2026, 06:30 UTC

Omandamised, ülevõtmised, äriostud

Bayer To Acquire Perfuse Therapeutics To Complement Ophthalmology Pipeline >BAYN.XE

8. apr 2026, 14:41 UTC

Tulu

Buy Johnson & Johnson Stock Ahead of Earnings, Analyst Says. The Gains Can Continue. -- Barrons.com

1. apr 2026, 14:24 UTC

Market Talk

Bayer Pharma Head Touts Healthiest Pipeline in Company's History -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Bayer AG Prognoos

Hinnasiht

By TipRanks

25.11% tõus

12 kuu keskmine prognoos

Keskmine 48.18 EUR 25.11%

Kõrge 56 EUR

Madal 25 EUR

Põhineb 12 Wall Streeti analüütiku instrumendi Bayer AG 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

12 ratings

Osta

Hoia

Müü

Põhineb 12 analüütiku instrumendi Bayer AG aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

91 / 438 Pingereas Rahandus

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Bayer AG

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment provides breeding, propagation, and production/processing of seeds, including seed dressing. It has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc.; strategic research partnership with University of Oxford to develop novel gynecological therapies; Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases; and collaboration and license agreement with Cytokinetics for the development and commercialization of aficamten. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company was founded in 1863 and is headquartered in Leverkusen, Germany.